Serina Therapeutics (SER) Corporate presentation summary

Platform innovation and technology

• POZ platform enables improvements in small molecules, RNA, and ADCs, offering optimized targeting, reduced immunogenicity, and improved delivery of cancer therapies.

• POZ (poly 2-oxazoline) addresses limitations of other polymers, allowing greater drug loading, controlled release, and safe metabolism.

• Platform supports cost-effective, stable synthesis and does not elicit immune responses.

Lead asset and clinical development

• Lead program SER-252 (POZ-apomorphine) targets advanced Parkinson's disease, with clinical entry planned for 2025.

• SER-252 enables continuous dopaminergic stimulation without electronic pumps or adverse skin reactions, addressing key limitations of current therapies.

• Preclinical studies show no skin reactions, a significant improvement over existing apomorphine products.

• Phase 1 trial in advanced Parkinson's patients will begin in 2025, with interim data expected in 2026.

Market opportunity and competitive landscape

• Advanced Parkinson's disease affects 150,000 patients in the US and 210,000 in EU/UK, with about half inadequately controlled on oral therapies.

• SER-252 has a projected peak sales opportunity of $1.4B to $2.2B in the US/EU/UK.

• Competing products require invasive, continuously worn infusion devices, while SER-252 offers a differentiated, wearable device with less frequent dosing.

• Partnership with Enable Injections provides a compact, user-friendly delivery device for SER-252.